Yamasaki Megumi, Sato Yasushi, Okamoto Koichi, Fukuya Akira, Kawaguchi Tomoyuki, Noda Kazuyoshi, Kagemoto Kaizo, Mitsui Yasuhiro, Miyamoto Hiroshi, Takayama Tetsuji
Department of Gastroenterology, Tokushima Red Cross Hospital, 103 Irinokuchi, Komatsushima-Cho, Komatsushima, Tokushima, 773-8502, Japan.
Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, 3-18-15 Kuramoto-Cho, Tokushima, 770-8503, Japan.
Clin J Gastroenterol. 2023 Apr;16(2):180-186. doi: 10.1007/s12328-022-01736-z. Epub 2022 Nov 21.
Anal squamous cell carcinoma (ASCC) is an uncommon tumor. However, its incidence is increasing worldwide. Surgical resection of locally advanced cases requires permanent anal prosthesis. Thus, chemoradiotherapy (CRT) is preferred as the first-line treatment; however, high local recurrence rate remains an issue. Here, we describe two cases of locally advanced ASCC treated with docetaxel + cisplatin + S-1 (DCS) followed by CRT with S-1 that showed complete response. The two patients, aged 69 and 65 years, were diagnosed with ASCC (cStage IIIB) at our hospital. Due to extensive lymph node metastases, the patients were treated with triple induction chemotherapy (DCS) followed by CRT with S-1. Positron emission tomography/computed tomography performed six months after starting the treatment showed disappearance of tumors, indicating a complete response. The patients continued to receive S-1 for one year and achieved relapse-free long-term survival since the completion of treatment. Therefore, induction chemotherapy with DCS, prior to CRT with S-1 may benefit patients with locally advanced ASCC.
肛管鳞状细胞癌（ASCC）是一种罕见肿瘤。然而，其在全球范围内的发病率正在上升。局部晚期病例的手术切除需要永久性肛门假体。因此，化疗放疗（CRT）作为一线治疗更受青睐；然而，高局部复发率仍然是一个问题。在此，我们描述了两例局部晚期ASCC患者，他们接受了多西他赛+顺铂+S-1（DCS）治疗，随后接受S-1同步放化疗，均显示完全缓解。这两名患者年龄分别为69岁和65岁，在我院被诊断为ASCC（临床分期IIIB期）。由于广泛的淋巴结转移，患者接受了三联诱导化疗（DCS），随后接受S-1同步放化疗。治疗开始六个月后进行的正电子发射断层扫描/计算机断层扫描显示肿瘤消失，表明完全缓解。患者继续接受S-1治疗一年，自治疗完成后实现了无复发生存的长期生存。因此，在S-1同步放化疗之前使用DCS进行诱导化疗可能使局部晚期ASCC患者受益。
